The SARS-CoV-2 infection detected in China in December 2019 is responsible for the current COVID-19 pandemic affecting nearly 1.2 million people worldwide to date. Infection with this virus of the coronavirus family is causing a broad clinical spectrum, the main manifestation of which is an influenza-like condition associated with a pattern of severe hypoxemia pneumonia, and in some cases fatal. Little is known about this pathology, so we propose to carry out an observational cohort of patients treated in our hospital for an SARS-CoV-2 infection. This cohort should make it possible to clinically, biologically and radiologically characterize the SARS-CoV-2 infections. We will also collect the therapeutic strategies implemented, their possible toxicity and the evolution of the patients.
COVID-19 is a virus belonging to the coronavirus family, which includes a large number of
viruses that can cause a wide variety of diseases in humans. The SARS-CoV-2 virus that caused
the current COVID-19 pandemic, although widely described in the literature, still has many
grey areas. The main clinical manifestation is an influenza-like illness associated with
respiratory tract infection that can lead to severe hypoxemic pneumonia with fatal outcomes
in 2.3% of cases. The clinical spectrum is not yet very well known, as evidenced by the
evidence of anosmia, agueusia, or recent skin manifestations, but also strong suspicion of
possible neurological damage. Similarly, it is not yet very well established, apart from
certain co-morbidities, which patients are likely to develop serious forms requiring
admission to intensive care, as shown by the proportion of patients < 60 years of age
admitted to intensive care for ARDS.
Moreover, the question of how to manage these patients still raises many questions,
particularly about the type of molecules to be introduced and at what point in the history of
the disease. Some of these molecules, such as the Lopinavir/Ritonavir combinations and the
Hydroxychloroquine/ Azithromycin combination, are not free of complications, particularly
cardiac complications requiring close monitoring by ECGs and repeated dosing, the
effectiveness of which has not yet been clearly demonstrated.
In order to better understand this infection, we propose to set up a cohort of patients
treated for CoV-2 SARS infection on our site.
Study scheme:
Longitudinal cohort study of patients with confirmed or strongly suspected CoV-2 SARS
infection.
Inclusion criteria:
- Patient ≥ 18 years old
- SARS-CoV-2 infection confirmed by PCR or strongly suspected on compatible
radio-clinical grounds during an epidemic period.
Exclusion criteria:
- Not able to express their opposition
- Patient under guardianship or curatorship
Department of Infectiology, Raymond Poincaré Hospital, APHP
Garches, France
Aurelien Dinh, MD
+33 1 47 10 77 74
Aurelien.dinh@aphp.fr
Simon Bessis, MD
+33 1 47 10 77 74
simon.bessis@aphp.fr